

Product Data Sheet

Dilmapimod

Cat. No.: HY-10404 CAS No.: 444606-18-2 Molecular Formula: $C_{23}H_{19}F_3N_4O_3$ Molecular Weight: 456.42

Target: p38 MAPK; Autophagy

Pathway: MAPK/ERK Pathway; Autophagy

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 125 mg/mL (273.87 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.1910 mL	10.9548 mL	21.9096 mL
	5 mM	0.4382 mL	2.1910 mL	4.3819 mL
	10 mM	0.2191 mL	1.0955 mL	2.1910 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.56 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: \ge 2.08 mg/mL (4.56 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.56 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	Dilmapimod (SB-681323) is a potent p38 MAPK inhibitor that potentially suppresses inflammation in chronic obstructive pulmonary disease.
In Vitro	Dilmapimod (SB-681323) potently inhibits p38 MAPK signaling, measured by inhibition of sorbitol-induced pHSP27 expression ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

• Cell. 2020 Aug 6;182(3):685-712.e19.

See more customer validations on $\underline{www.MedChemExpress.com}$

REFERENCES

[1]. Singh D, et al. A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients. J Clin Pharmacol. 2010 Jan;50(1):94-100.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA